Sirolimus plus fulvestrant for advanced HR+/HER2- breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests a new combination of sirolimus (a targeted therapy) and fulvestrant (a hormone therapy) for people with advanced HR+/HER2- breast cancer whose disease has progressed after prior treatment with a CDK4/6 inhibitor. The goal is to see if the combination can help control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older and have advanced or metastatic HR+/HER2- breast cancer that cannot be cured with surgery or radiation.
- You have already received at least one line of hormone therapy combined with a CDK4/6 inhibitor, but not more than two lines of treatment for advanced disease.
- You have not previously taken any drugs that target the PI3K/AKT/mTOR pathway, fulvestrant, or other experimental estrogen-blocking drugs.
- You are in generally good health (able to care for yourself) and have adequate organ function.
- You are willing to provide a tumor or blood sample for testing, or your doctor agrees you can join without it.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new form of sirolimus (a targeted drug) combined with palbociclib and fulvestrant for advanced breast cancer that is hormone-sensitive and HER2-negative. It may be an option if you have already tried hormone therapy and it stopped working.
This trial tests a new combination of three drugs (sirolimus, palbociclib, and fulvestrant) for people with a certain type of advanced breast cancer that is hormone receptor-positive and HER2-negative. The goal is to see if adding sirolimus can help control the cancer when standard hormone therapy is no longer working.
This trial tests a new study medicine (PF-07248144) combined with fulvestrant in people with a certain type of advanced breast cancer (HR-positive, HER2-negative) that has worsened after previous treatments. It may be an option if you've already tried a CDK4/6 inhibitor and endocrine therapy.
This trial tests a new drug, HRS-6209, combined with other treatments for people with hormone receptor-positive, HER2-negative cancer. The goal is to see if the combination is safe and works well.
This trial studies whether adding anlotinib (a targeted medicine) to fulvestrant (a hormone-blocking injection) can improve outcomes for people with advanced HR-positive, HER2-negative breast cancer. It focuses on safety and effectiveness when cancer has returned or progressed after hormone treatments.
This trial tests a new drug, HRS-6209, combined with different hormone treatments (fulvestrant, letrozole, HRS-8080, or HRS-1358) for people with advanced breast cancer that has spread or cannot be surgically removed and has worsened after previous treatments.
Hear when a new HR+/HER2- Advanced/Metastatic Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.